Free tool
FAERS Monitor: Carospir
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 209478 or its brand name (Carospir, Spironolactone). Reports on generic versions are filed under their own applications.
Reports
114,068
Serious
86,569
76% of reports
Hospitalization
51,031
Death reported
13,594
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- dyspnoea9,056
- fatigue7,400
- nausea6,911
- diarrhoea6,535
- acute kidney injury5,703
- dizziness5,651
- headache5,543
- off label use5,180
- drug ineffective4,907
- hypotension4,890
- fall4,218
- death4,158
- asthenia4,144
- vomiting4,134
- cough3,866
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 925 |
| 2005 | 1,121 |
| 2006 | 1,073 |
| 2007 | 1,069 |
| 2008 | 1,201 |
| 2009 | 1,459 |
| 2010 | 1,968 |
| 2011 | 2,150 |
| 2012 | 2,739 |
| 2013 | 2,708 |
| 2014 | 3,550 |
| 2015 | 5,261 |
| 2016 | 6,809 |
| 2017 | 6,304 |
| 2018 | 7,722 |
| 2019 | 8,404 |
| 2020 | 7,887 |
| 2021 | 7,806 |
| 2022 | 7,969 |
| 2023 | 8,769 |
| 2024 | 9,708 |
| 2025 | 9,761 |
| 2026 | 7,704 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 20,940,091 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| acute kidney injurySignal | 5,703 | 7.1 | 6.9 | 28,973 |
| hypotensionSignal | 4,890 | 4.6 | 4.5 | 13,486 |
| dyspnoeaSignal | 9,056 | 3.0 | 2.9 | 12,057 |
| coughSignal | 3,866 | 2.6 | 2.5 | 3,683 |
| fallSignal | 4,218 | 2.4 | 2.3 | 3,294 |
| dizzinessSignal | 5,651 | 2.1 | 2.0 | 3,303 |
| astheniaSignal | 4,144 | 2.0 | 2.0 | 2,223 |
| diarrhoea | 6,535 | 1.9 | 1.8 | 2,727 |
| fatigue | 7,400 | 1.8 | 1.7 | 2,496 |
| headache | 5,543 | 1.6 | 1.6 | 1,399 |
| vomiting | 4,134 | 1.6 | 1.6 | 1,012 |
| nausea | 6,911 | 1.6 | 1.6 | 1,669 |
| off label use | 5,180 | 1.1 | 1.1 | 41 |
| death | 4,158 | 0.9 | 0.9 | 59 |
| drug ineffective | 4,907 | 0.7 | 0.7 | 753 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.